摘要
目的:研究恩替卡韦联合熊去氧胆酸治疗活动性乙肝失代偿期的临床疗效。方法:选取我院2008年至2012年间就诊的68例乙肝失代偿患者,随机分为恩替卡韦+熊去氧胆酸联合治疗组(n=40)和对照组(n=28),给予对照组基本治疗,联合治疗组在此基础上给予恩替卡韦联合熊去氧胆酸,疗程为48w。观察患者治疗前后临床表现,肝功能指标,HBV-DNA拷贝数,Child-Plugh评分变化。结果:两组患者治疗前后丙氨酸转氨酶(ALT)、门冬氨酸转移酶(AST)、谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)有明显改善;总胆红素(TBIL)、总胆汁酸(TBA)、血清球蛋白(Glo)、总胆固醇(TCho)、Child-Pugh等指标用药组有显著改善,对照组无显著改善;治疗组中HBV-DNA拷贝数小于1000.ml-1的例数显著提高,而对照组中几乎没有明显变化。结论:恩替卡韦联合熊去氧胆酸对治疗活动性乙肝失代偿期有突出的退黄降酶、抑制病毒复制作用,并且无明显不良反应和药物相互作用,值得临床进一步研究和推广。
Objective： To study the clinical efficacy of entecavir with ursodeoxycholic acid to hepatitis B cirrhosis in decompensa- tion stage. Methods： Patients with hepatitis B of decompensated stage were randomly divided into two groups： 40 cases in combined treatment group and 28 cases in control group. Basic treatment was given in control group and additional treatment of entecavir and ursodeoxycholic acid was given to in combined treatment group. Clinical symptoms, liver function indicators, copies of HBV-DNA, Child-Plugh index were recorded. Treatment maintained for 48 weeks. Results; Clinical symptoms, indicators of liver function were significantly improved in the combined treatment group, and the number of HBV-DNA copy decreased significantly in the combined treatment group. Conclusion： Combination therapy of Enteeavir and Ursodeoxycholic acid plays an important role in the treatment of active hepatitis B with decompensated stage and improve the disease effectively.
出处
《四川生理科学杂志》
2012年第4期162-164,共3页
Sichuan Journal of Physiological Sciences
作者简介
作者简介：刘平，男，住院医师，主要从事内科临床工作．Email：4966794@qq．com。
